Query: stroke

Filtered By:
Source: European Heart Journal
Condition: Atrial Fibrillation

This page shows you your search results in order of date.

Order by Relevance | Date

Total 89 results found since Jan 2013.

Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
Source: European Heart Journal - September 21, 2019 Category: Cardiology Source Type: research

Corrigendum to: Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management
[Eur Heart J 2019;40:3058 –3059].
Source: European Heart Journal - August 19, 2019 Category: Cardiology Source Type: research

Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management
This commentary refers to ‘Risk stratification for stroke in atrial fibrillation: a critique’, by A.M. Killuet al., 2019;40:1294 –1302.
Source: European Heart Journal - July 13, 2019 Category: Cardiology Source Type: research

Response to: Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management
This commentary refers to ‘Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management’†, by H.-F. Liet al., 2019;40:3058 –3059.
Source: European Heart Journal - July 13, 2019 Category: Cardiology Source Type: research

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
ConclusionUninterrupted edoxaban therapy represents an alternative to uninterrupted VKA treatment in patients undergoing AF ablation.
Source: European Heart Journal - April 11, 2019 Category: Cardiology Source Type: research

‘Ten Commandments’ of the EHRA Guide for the Use of NOACs in AF
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF), and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. In 2013, the first “EHRA Practical Guide” was published to provide practical guidance for situations; an update was published in 2015. Below ...
Source: European Heart Journal - April 21, 2018 Category: Cardiology Source Type: research

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
ConclusionCompared with TAT, DAT shows a reduction in TIMI major or minor bleeding by 47% with comparable outcomes of MACE. Our findings support the concept that DAT may be a better option than TAT in many patients with AF following PCI.
Source: European Heart Journal - April 13, 2018 Category: Cardiology Source Type: research

Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials
ConclusionIn selected patients with cryptogenic stroke, PFO closure is superior to medical therapy for the prevention of further stroke: this is particularly true for patients with moderate-to-large shunts. Guidelines should be updated to reflect this.
Source: European Heart Journal - March 24, 2018 Category: Cardiology Source Type: research

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
AbstractThe current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchelet al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace 2013;15:625 –651; Heidbuchelet al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467 –1507]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in pati...
Source: European Heart Journal - March 19, 2018 Category: Cardiology Source Type: research

Prediction of ischaemic stroke in non-valvular atrial fibrillation if advanced echocardiography plays the game
Abstract
Source: European Heart Journal - February 9, 2018 Category: Cardiology Source Type: research

Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis
ConclusionSubclinical AF strongly predicts clinical AF and is associated with elevated absolute stroke risk albeit lower than risk described for clinical AF.
Source: European Heart Journal - January 10, 2018 Category: Cardiology Source Type: research

The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation
This editorial refers to ‘Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry’††, by F.W.A. Verheugtet al., on page 464.
Source: European Heart Journal - January 9, 2018 Category: Cardiology Source Type: research

Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation
Abstract
Source: European Heart Journal - January 6, 2018 Category: Cardiology Source Type: research

Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation
ConclusionTelemonitoring resulted in high NOAC adherence due to the notion of being watched, as evidenced by the rapid decline during the observation period. Feedback further optimized adherence. Telemonitoring with or without feedback may be a cost-effective approach in high-risk patients deemed poorly adherent.
Source: European Heart Journal - January 2, 2018 Category: Cardiology Source Type: research

Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry
ConclusionThe assessment of LA reservoir strain and PA-TDI on echocardiography after initial CHA2DS2-VASc scoring provides additional risk stratification for stroke and may be useful to guide decisions regarding anticoagulation for patients upon first diagnosis of AF.
Source: European Heart Journal - December 28, 2017 Category: Cardiology Source Type: research

Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry
ConclusionPrescribing AP monotherapy in newly diagnosed AF has declined, but even nowadays a substantial proportion of AP-treated patients with AF have no indication for AP.Clinical Trial RegistrationURL:http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
Source: European Heart Journal - December 20, 2017 Category: Cardiology Source Type: research

Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation
This editorial refers to ‘Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study’††, by L. Staerket al., on page 1698.
Source: European Heart Journal - December 13, 2017 Category: Cardiology Source Type: research

Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study
ConclusionAF patients resuming VKA and NOAC treatment following traumatic injury have lower hazard of all-cause mortality and ischaemic stroke, increased hazard of major bleeding but without additional hazards of recurrent traumatic injury. Withholding OAC following a traumatic injury in AF patients may not be warranted.
Source: European Heart Journal - November 18, 2017 Category: Cardiology Source Type: research

A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea
ConclusionCPAP therapy might reduce MACE and stroke among subjects with CPAP time exceeding 4  h/night. Additional randomized trials mandating adequate CPAP time adherence are required to confirm this impression.
Source: European Heart Journal - October 24, 2017 Category: Cardiology Source Type: research

Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation
Improving anticoagulation rates and stroke outcomes by collaborative working and application of the simple ‘Birmingham 3-step’ approach
Source: European Heart Journal - October 21, 2017 Category: Cardiology Source Type: research

Uncommon cause of dyspnoea after percutaneous closure of the left atrial appendage
A 69-year-old female with persistent atrial fibrillation and history of recurrent strokes presented with progressive shortness of breath. Three years ago, percutaneous closure of the left atrial appendage (LAA) for stroke prophylaxis was performed using an Amplatzer Amulet® device (St. Jude Medical, MN, USA).
Source: European Heart Journal - August 1, 2017 Category: Cardiology Source Type: research

Long working hours as a risk factor for atrial fibrillation: a multi-cohort study
ConclusionIndividuals who worked long hours were more likely to develop atrial fibrillation than those working standard hours.
Source: European Heart Journal - July 13, 2017 Category: Cardiology Source Type: research

Corrigendum to: Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials
Eur Heart J (2017) 38 (10):742 –750.
Source: European Heart Journal - June 1, 2017 Category: Cardiology Source Type: research

Atrial fibrillation as a risk factor for cognitive decline and dementia
ConclusionIn adults aged 45 –85 years AF is associated with accelerated cognitive decline and higher risk of dementia even at ages when AF incidence is low. At least in part, this was explained by incident cardiovascular disease in patients with AF.
Source: European Heart Journal - April 29, 2017 Category: Cardiology Source Type: research

Subclinical atrial fibrillation in need of more assertive evidence
<span class="paragraphSection"><strong>This editorial refers to ‘Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT’†<sup> †</sup>, by I.C. Van Gelder<span style="font-style:italic;">et al.</span>, on page<strong><a href="article.aspx?volume=&page=">1339<span></span></a></strong>.</strong></span>
Source: European Heart Journal - March 31, 2017 Category: Cardiology Source Type: research

Female gender as a risk factor for stroke associated with atrial fibrillation
This editorial refers to ‘Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study’†, by C. Renouxet al., on page1473.
Source: European Heart Journal - March 27, 2017 Category: Cardiology Source Type: research

Foreign body granuloma as an unexpected long-term finding after percutaneous closure of a patent foramen ovale
A 67-year-old man was referred to our hospital for catheter ablation of atrial fibrillation. Eight years earlier, prior to diagnosis of atrial fibrillation, the patient suffered an ischaemic stroke. A patent foramen ovale (PFO) was diagnosed and the patient underwent percutaneous PFO closure by implantation of a Premere device (20  mm, St. Jude Medical). One month ago, the patient had another middle-cerebral artery infarction, which was considered cardioembolic due to insufficient anticoagulation. However, transthoracic echocardiography (TTE) obtained on current admission demonstrated a suspicious mass in the left atrium...
Source: European Heart Journal - March 24, 2017 Category: Cardiology Source Type: research

Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry
Conclusion</div>Ablation therapy for SVT is a safe procedure bringing symptomatic improvement and satisfaction to three quarters of patients after 1 year. Even in patients with arrhythmia recurrence, a high satisfaction level and adherence to the ablating institution could be documented. Strikingly high mortality and stroke rates in follow-up were observed in AFL patients, who apparently need consistent long-term anticoagulation and more medical attention.</span>
Source: European Heart Journal - March 17, 2017 Category: Cardiology Source Type: research

Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT
Conclusions</div>SCAF>24  h is associated with an increased risk of ischemic stroke or systemic embolism.</span>
Source: European Heart Journal - March 1, 2017 Category: Cardiology Source Type: research

Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update
AbstractSubclinical thyroid dysfunction comprises subclinical hypothyroidism (SHypo), defined as elevated thyroid-stimulating hormone (TSH) by normal free thyroxine (FT4), and subclinical hyperthyroidism (SHyper) with decreased or undetectable TSH and normal FT4. Up to 10% of the elderly have SHypo, which is usually asymptomatic. Individual participant data (IPD) analyses of prospective cohort studies from the international Thyroid Studies Collaboration show that SHypo is associated with increased coronary heart disease (CHD) mortality [hazard ratio (HR) 1,58 for TSH ≥ 10 mIU/L, 95% CI 1.10–2.27), as well as increased ...
Source: European Heart Journal - February 27, 2017 Category: Cardiology Source Type: research

Stroke prevention in Atrial Fibrillation
<span class="paragraphSection"><strong>Prof. Gregory Lip discusses how to keep the decision-making process for choosing an oral anticoagulant simple and practical</strong> </span>
Source: European Heart Journal - January 21, 2017 Category: Cardiology Source Type: research

Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark
Conclusion</div>Since 2010, more incident AF patients in Denmark were initiated on OAC therapy with predominant NOAC prescription. The increase was pronounced among females, among patients at high risk of stroke, and among older patients.</span>
Source: European Heart Journal - January 20, 2017 Category: Cardiology Source Type: research

Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study
ConclusionIn NVAF, women were not at higher risk of thromboembolic events than men in our study. The small increased risk reported in previous studies may be related to residual confounding, in particular from insufficient control for age.
Source: European Heart Journal - January 10, 2017 Category: Cardiology Source Type: research

Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium
Conclusion</div>Ticagrelor, but not CAM, reduces expression and activity of TF and PAI-1 in LAA endocardial cells isolated from patients with AF, indicating possible local antithrombotic effects. Such pleiotropic properties of ticagrelor may contribute to a reduction in thromboembolic complications in patients with AF.</span>
Source: European Heart Journal - January 8, 2017 Category: Cardiology Source Type: research

A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial
Conclusion</div>In VKA naive patients with AF, the TIMI-AF score can assist in the prediction of a poor composite outcome and guide selection of anticoagulant therapy by identifying a differential clinical benefit with a NOAC or VKA.</span>
Source: European Heart Journal - January 7, 2017 Category: Cardiology Source Type: research

Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation
Conclusion Left atrial appendage closure in NVAF in a real-world setting may result in lower stroke and major bleeding rates than reported in LAAC clinical trials. Left atrial appendage closure in both settings achieves cost parity in a relatively short period of time and may offer substantial savings compared with current therapies. Savings are most pronounced among higher risk patients and those unsuitable for anticoagulation.
Source: European Heart Journal - December 30, 2016 Category: Cardiology Authors: Panikker, S., Lord, J., Jarman, J. W. E., Armstrong, S., Jones, D. G., Haldar, S., Butcher, C., Khan, H., Mantziari, L., Nicol, E., Hussain, W., Clague, J. R., Foran, J. P., Markides, V., Wong, T. Tags: Thrombosis and antithrombotic therapy Source Type: research

Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation
Conclusion In this SAF cohort, the ATRIA score predicted ischaemic stroke risk better than CHADS2 or CHA2DS2-VASc. However, relative performance of the categorical scores varied by population stroke rates. Score cut-points may need to be optimized to better fit local population stroke rates.
Source: European Heart Journal - November 17, 2016 Category: Cardiology Authors: Aspberg, S., Chang, Y., Atterman, A., Bottai, M., Go, A. S., Singer, D. E. Tags: Prevention and epidemiology Source Type: research

Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials
Conclusions</div>A small number of clinical variables identify a subset of patients with HF-PEF, but without AF, at elevated risk of stroke.</span>
Source: European Heart Journal - November 13, 2016 Category: Cardiology Source Type: research

Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study
Conclusions</div>Among anticoagulant-naïve AF patients, treatment with NOACs was not associated with significantly lower risk of stroke/TE compared with VKA, but intracranial bleeding risk was significantly lower with dabigatran and apixaban.</span>
Source: European Heart Journal - October 14, 2016 Category: Cardiology Source Type: research

Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries
Conclusion Ablation may be associated with lower incidence of ischaemic stroke and death in patients with AF. This beneficial finding appears more pronounced in patients with higher thromboembolic risk.
Source: European Heart Journal - August 24, 2016 Category: Cardiology Authors: Friberg, L., Tabrizi, F., Englund, A. Tags: Arrhythmia/electrophysiology Source Type: research

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation
Conclusion A novel biomarker-based risk score for predicting stroke in AF was successfully developed and internally validated in a large cohort of patients with AF and further externally validated in an independent AF cohort. The ABC-stroke score performed better than the presently used clinically based risk score and may provide improved decision support in AF. ClinicalTrials. gov identifier NCT00412984, NCT00799903.
Source: European Heart Journal - May 21, 2016 Category: Cardiology Authors: Hijazi, Z., Lindback, J., Alexander, J. H., Hanna, M., Held, C., Hylek, E. M., Lopes, R. D., Oldgren, J., Siegbahn, A., Stewart, R. A. H., White, H. D., Granger, C. B., Wallentin, L., the ARISTOTLE and STABILITY Investigators Tags: Atrial fibrillation Source Type: research

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Conclusion XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number Clinicaltrials.gov: NCT01606995.
Source: European Heart Journal - April 7, 2016 Category: Cardiology Authors: Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., van Eickels, M., Turpie, A. G. G., the XANTUS Investigators Tags: Atrial fibrillation Source Type: research

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
<span class="paragraphSection">Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral anticoagulants (NOACs) were compared with warfarin in large randomized trials for the prevention of stroke and systemic embolism. Today's clinician is faced with the difficult task of selecting a suitable OAC for a patient with a particular clinical profile or a particular pattern of risk factors and concomitant diseases. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. NOA...
Source: European Heart Journal - February 4, 2016 Category: Cardiology Source Type: research

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
<span class="paragraphSection">The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be influenced by individual clinical features or by patterns of risk factors and comorbidities. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. non-vitamin K oral anticoagulants (NOACs) for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another. In addition, we discuss the timing of initiation of anticoagulation. In the second of a two-part review, we discuss the use of NOAC for stroke prevent...
Source: European Heart Journal - February 4, 2016 Category: Cardiology Source Type: research

Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES
Conclusion In a large population of non-anticoagulated AF patients, pattern of AF was a strong independent predictor of stroke risk and may be helpful to assess the risk/benefit for anticoagulant therapy, especially in lower risk patients.
Source: European Heart Journal - February 2, 2015 Category: Cardiology Authors: Vanassche, T., Lauw, M. N., Eikelboom, J. W., Healey, J. S., Hart, R. G., Alings, M., Avezum, A., Diaz, R., Hohnloser, S. H., Lewis, B. S., Shestakovska, O., Wang, J., Connolly, S. J. Tags: Atrial fibrillation Source Type: research

Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial
Conclusion In patients with AF at moderate-to-high risk of stroke receiving anticoagulation, those with persistent AF have a higher risk of thrombo-embolic events and worse survival compared with paroxysmal AF.
Source: European Heart Journal - February 2, 2015 Category: Cardiology Authors: Steinberg, B. A., Hellkamp, A. S., Lokhnygina, Y., Patel, M. R., Breithardt, G., Hankey, G. J., Becker, R. C., Singer, D. E., Halperin, J. L., Hacke, W., Nessel, C. C., Berkowitz, S. D., Mahaffey, K. W., Fox, K. A. A., Califf, R. M., Piccini, J. P., on be Tags: Atrial fibrillation Source Type: research

Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study
Conclusions Patients with both AF and renal failure will probably benefit most from having the same treatment as is recommended for other patients with AF, without setting a higher or lower threshold for treatment. Adding additional points for renal failure to the CHADS2 and CHA2DS2-VASc scores did not improve their predictive value.
Source: European Heart Journal - February 2, 2015 Category: Cardiology Authors: Friberg, L., Benson, L., Lip, G. Y. H. Tags: Atrial fibrillation Source Type: research

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
Conclusion The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Halvorsen, S., Atar, D., Yang, H., De Caterina, R., Erol, C., Garcia, D., Granger, C. B., Hanna, M., Held, C., Husted, S., Hylek, E. M., Jansky, P., Lopes, R. D., Ruzyllo, W., Thomas, L., Wallentin, L. Tags: Atrial fibrillation Source Type: research

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
Conclusions Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Dorian, P., Kongnakorn, T., Phatak, H., Rublee, D. A., Kuznik, A., Lanitis, T., Liu, L. Z., Iloeje, U., Hernandez, L., Lip, G. Y. H. Tags: BASIC SCIENCE Source Type: research